Based on the Amgen Inc stock forecast from 15 analysts, the average analyst target price for Amgen Inc is USD 343.66 over the next 12 months. Amgen Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Amgen Inc is Neutral, which is based on 8 positive signals and 7 negative signals. At the last closing, Amgen Inc’s stock price was USD 294.53. Amgen Inc’s stock price has changed by +3.85% over the past week, -6.70% over the past month and +10.95% over the last year.
No recent analyst target price found for Amgen Inc
No recent average analyst rating found for Amgen Inc
Company Overview Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. Address: One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 Read Less
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, pso...Read More
Frequently Asked Questions About Amgen Inc (AMGN) Stock
Based on ratings from 15 analysts Amgen Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Neutral. The stock has 16 buy, 1 sell and 12 hold ratings.
AMGN stock's dividend yield is 3.06%.
Our analysis grades AMGN stock's dividend yield at F. This means that AMGN stock's dividend yield is above 50% of the stocks in the Drug Manufacturers - General sector in the NSD exchange.
Based on this AMGN may be a average dividend stock for its sector.
Based on targets from 15 analysts, the average taret price for AMGN is USD 343.66 over the next 12 months. The maximum analyst target price is USD 405 while the minimum anlayst target price is USD 215.
AMGN stock's Price/Earning ratio is 37.62.
Our analysis grades AMGN stock's Price / Earning ratio at F. This means that AMGN stock's Price/Earning ratio is above 57.00000000000001% of the stocks in the Drug Manufacturers - General sector in the NSD exchange.
Based on this AMGN may be a overvalued for its sector.
The last closing price of AMGN's stock was USD 294.53.
The most recent market capitalization for AMGN is USD 158.32B.
Based on targets from 15 analysts, the average taret price for AMGN is projected at USD 343.66 over the next 12 months.
This means that AMGN's stock price may go up by +16.68% over the next 12 months.
We can't find any ETFs which contains Amgen Inc's stock.
As per our most recent records Amgen Inc has 26,700 Employees.
Amgen Inc's registered address is One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799.
You can get more information about it from Amgen Inc's website at https://www.amgen.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High dividend returns
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Amgen Inc (AMGN) Stock
Based on ratings from 15 analysts Amgen Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Neutral. The stock has 16 buy, 1 sell and 12 hold ratings.
AMGN stock's dividend yield is 3.06%.
Our analysis grades AMGN stock's dividend yield at F. This means that AMGN stock's dividend yield is above 50% of the stocks in the Drug Manufacturers - General sector in the NSD exchange.
Based on this AMGN may be a average dividend stock for its sector.
Based on targets from 15 analysts, the average taret price for AMGN is USD 343.66 over the next 12 months. The maximum analyst target price is USD 405 while the minimum anlayst target price is USD 215.
AMGN stock's Price/Earning ratio is 37.62.
Our analysis grades AMGN stock's Price / Earning ratio at F. This means that AMGN stock's Price/Earning ratio is above 57.00000000000001% of the stocks in the Drug Manufacturers - General sector in the NSD exchange.
Based on this AMGN may be a overvalued for its sector.
The last closing price of AMGN's stock was USD 294.53.
The most recent market capitalization for AMGN is USD 158.32B.
Based on targets from 15 analysts, the average taret price for AMGN is projected at USD 343.66 over the next 12 months.
This means that AMGN's stock price may go up by +16.68% over the next 12 months.
We can't find any ETFs which contains Amgen Inc's stock.
As per our most recent records Amgen Inc has 26,700 Employees.
Amgen Inc's registered address is One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799.
You can get more information about it from Amgen Inc's website at https://www.amgen.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AMGN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
